December 9, 2020 Regulatory Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB Read more
November 25, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2020 Read more
November 25, 2020 Regulatory InDex Pharmaceuticals intends to carry out a fully guaranteed rights issue of approximately SEK 500 million to fund phase III development of cobitolimod Read more
August 26, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2020 Read more
May 7, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2020 Read more
April 20, 2020 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 16, 2020 Regulatory InDex Pharmaceuticals advances cobitolimod further towards phase III following successful interactions with FDA and EMA Read more
March 30, 2020 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2019 Read more
March 19, 2020 Regulatory Notice to attend the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
February 19, 2020 Regulatory InDex Pharmaceuticals’ in-depth analysis of the CONDUCT study confirms the successful top line results and supports the strategy going forward Read more